1610413-97-2

Basic information

• Product Name: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid
• Synonyms: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid
• CAS NO: 1610413-97-2
• Molecular Formula: C₃₄H₅₄N₄O₁₀
• Molecular Weight: 678.81336
• Product Categories: ADCs;ADC
• Mol File: 1610413-97-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 837.7±65.0 °C(Predicted)
• Appearance: /
• Density: 1.156±0.06 g/cm3(Predicted)
• PKA: 4.34±0.10(Predicted)
• CAS DataBase Reference: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid(1610413-97-2)
• EPA Substance Registry System: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid(1610413-97-2)

Safety Data

• Hazardous Substances Data: 1610413-97-2(Hazardous Substances Data)

Usage

General Description

2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid is a complex chemical compound with a long and specific molecular structure. 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid is a derivative of phenylacetic acid and contains multiple functional groups, including carbonyl and t-butoxy carbonyl groups, as well as a tetraazanonadecyl chain. The presence of these groups and the unique structure of the compound make it potentially useful for various applications in organic chemistry, pharmaceuticals, and research. However, due to its complexity and specific properties, this chemical requires careful handling and analysis to determine its potential uses and effects.

Upstream product

• 5978-22-3 N(ε)-benzoyloxycarbonyl-L-lysine tert-butyl ester hydrochloride 
• 1025796-31-9 (S)-2-[3-((S)-5-amino-1-tert-butoxycarbonylpentyl)ureido]pentanedioic acid di-tert-butyl ester 
• 1200-05-1 2-(4-(aminomethyl)phenyl)acetic acid 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 1025796-30-8 (S)-2-[3-((S)-(5-benzyloxycarbonylamino)-1-tert-butoxycarbonylpentyl)ureido]pentanedioic acid di-tert-butyl ester 
• 32677-01-3 L-glutamic acid di-tert-butyl ester hydrochloride 
• 156079-00-4 di-tert-butyl <<(4-nitrophenyl)oxy>carbonyl>-L-glutamate 
• 1610413-98-3 C₃₁H₄₈N₄O₁₁ 
• 71420-92-3 2-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)acetic acid 

Downstream Products

• 1610414-00-0 C₃₃H₄₅N₇O₁₇S 

Relevant articles and documents

METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND

The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a PSMA ligand-tubulysin compound. The invention described herein also relates to methods of treating PSMA-expressing cancers with a PSMA ligand-tubulysin compound in patients where stable disease results after treatment with the PSMA ligand-tubulysin compound.

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.